In focus · trending topic

nonalcoholic steatohepatitis

3 stories · following the connections

Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Conference for NASH Summit Europe 2017

By Nasdaq OMXSep 25, 2017, 12:30 PM UTC

Galectin Therapeutics Announces Important Milestones towards Completion of NASH CX Trial

By Nasdaq OMXJun 13, 2017, 12:30 PM UTC

Galectin Therapeutics Reports Third Quarter 2016 Financial Results and Provides Business Update

By Nasdaq OMXNov 8, 2016, 1:00 PM UTC